Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole

Radiation Research

Volumn 169, Issue 6, 2008, Pages 677-688

  Koch, Cameron J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; PIMONIDAZOLE;

ANIMAL CELL; ANTIBODY BLOOD LEVEL; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; DRUG BINDING; DRUG METABOLISM; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NONHUMAN; OXIMETRY; OXYGEN TENSION; PRIORITY JOURNAL; RAT;

ANIMALS; AREA UNDER CURVE; CALIBRATION; CELL HYPOXIA; CELL LINE, TUMOR; ETANIDAZOLE; FLOW CYTOMETRY; HUMANS; HYDROCARBONS, FLUORINATED; KINETICS; MICROSCOPY, FLUORESCENCE; NITROIMIDAZOLES; OXYGEN; RADIATION-SENSITIZING AGENTS; RATS; TIME FACTORS;

RATTUS;

EID: 44849127313     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1305.1     Document Type: Article

References (47)

1. J. D. Chapman and C. J. Gillespie, Radiation-induced events and their time scale in mammalian cells. Adv. Radiat. Biol. 9, 143-198 (1981).
2. A. J. Varghese and G. F. Whitmore, Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Res. 40, 2165-2169 (1980).
3. J. D. Chapman, Hypoxic sensitizers - implications for radiation therapy. New Engl. J. Med. 301, 1429-1432 (1979).
4. J. A. Raleigh and C. J. Koch, The importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol. 40, 2457-2464 (1990).
5. C. J. Koch and J. A. Raleigh, Radiolytic reduction of protein and non-protein disulfides in the presence of formate: a chain reaction. Arch. Biochem. Biophys. 287, 75-84 (1991).
6. J. D. Chapman, P. Zanzonico and C. C. Ling, On measuring of hypoxia in individual tumors with radiolabeled agents. J. Nucl. Med. 42, 653-655 (2001).
7. R. C. Urtasun, J. D. Chapman, J. A. Raleigh, A. J. Franko and C. J. Koch, Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 12, 1263-1267 (1986).
8. 2? Biochem. Pharmacol. 36, 3487-3494 (1987).
9. G. G. Miller, M. W. Best, A. J. Franko, C. J. Koch and J. A. Raleigh, Quantitation of hypoxia in multicellular spheroids by video image analysis. Int. J. Radiat. Oncol. Biol. Phys. 16, 949-952 (1989).
10. R. J. Hodgkiss, M. R. Stratford, M. F. Dennis and S. A. Hill, Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration. Br. J. Cancer 72, 1462-1468 (1995).
11. E. M. Lord, L. W. Harwell and C. J. Koch, Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53, 5271-5276 (1993).
12. C. J. Koch, The reductive activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems. In Selective Activation of Drugs by Redox Processes (G. E. Adams, A. Breccia, E. M. Fielden and P. Wardman, Eds.), pp. 237-247. Plenum Press, New York, 1990.
13. C. J. Koch, S. M. Evans and E. M. Lord, Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoroproply) acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br. J. Cancer 72, 869-874 (1995).
14. C. J. Koch, Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and the 2-nitroimidazole EF5. Methods Enzymol. 352, 3-31 (2002).
15. S. M. Evans, W. T. Jenkins, B. Joiner, E. M. Lord and C. J. Koch, 2-Nitroimidazole (EF5) binding predicts radiation sensitivity in individual 9L subcutaneous tumors. Cancer Res. 56, 405-411 (1996).
16. S. M. Evans, A. Schrlau, A. A. Chalian, P. Zhang and C. J. Koch, Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J. Invest. Dermatol. 126, 2596-2606 (2006).
17. G. E. Arteel, R. G. Thurman, J. M. Yates and J. A. Raleigh, Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br. J. Cancer 72, 889-895 (1995).
18. M. A. Varia, D. P. Calkins-Adams, L. H. Rinker, A. S. Kennedy, D. B. Novotny, W. C. Fowler and J. A. Raleigh, Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol. Oncol. 71, 270-277 (1998).
19. R. E. Durand and J. A. Raleigh, Identification of non-proliferating but viable hypoxic tumor cells in vivo. Cancer Res. 58, 3547-3550 (1998).
20. G. E. Arteel, R. G. Thurman and J. A. Raleigh, Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur. J. Biochem. 253, 743-750 (1998).
21. J. A. Raleigh, M. W. Dewhirst and D. E. Thrall, Measuring tumor hypoxia. Semin. Radiat. Oncol. 6, 37-45 (1996).
22. L. Goethals, A. Debucquoy, C. Perneel, K. Geboes, N. Ectors, H. de Schutter, F. Pennincyx, W. H. McBride, A. C. Begg and K. M. Haustermans, Hypoxia in human colorectal adenocarcinoma: comparisons between extrinsic and potential intrinsic hypoxia markers. Int. J. Radiat. Oncol. Biol. Phys. 65, 246-254 (2006).
23. S. Zoula, P. F. J. W. Rijken, J. P. W. Peters, R. Farion, B. P. J. Van der Sanden, A. J. Van der Kogel, M. Decorps and C. Remy, Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection. Br. J. Cancer 88, 1439-1444 (2003).
24. A. S. Ljungkvist, J. Bussink, P. F. Rijken, J. A. Raleigh, J. Denekamp and A. J. Van Der Kogel, Changes in tumor hypoxia measured with a double hypoxic marker technique. Int. J. Radiat. Oncol. Biol. Phys. 48, 1529-1538 (2000).
25. P. F. J. W. Rijken, H. J. J. A. Bernsen, J. P. W. Peters, R. J. Hodgkiss, J. A. Raleigh and A. J. van der Kogel, Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft. Int. J. Radiat. Oncol. Biol. Phys. 48, 571-581 (2000).
26. E. K. Rofstad and M. A. Maseide, Radiobiological and immunohistochemical assessment of hypoxia in human melanoma xenografts: acute and chronic hypoxia in individual tumours. Int. J. Radiat. Biol. 75, 1377-1393 (1999).
27. D. J. Chaplin, P. L. Olive and R. E. Durand, Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res. 47, 597-601 (1987).
28. A. S. E. Ljungkvist, J. Bussink, J. H. A. M. Kaanders and A. J. Van der Kogel, Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat. Res. 167, 127-145 (2007).
29. C. J. Koch, A thin-film culturing technique allowing rapid gas-liquid equilibration (6 seconds) with no toxicity to mammalian cells. Radiat. Res. 97, 434-442 (1984).
30. S. W. Tuttle, A. Maity, P. R. Oprysko, A. V. Kachur, I. S. Ayene, J. E. Biaglow and C. J. Koch, Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration: Implications for HIF-1 stability under moderate hypoxia. J. Biol. Chem. 282, 36790-36796 (2007).
31. A-M. Horan and C. J. Koch, The Km for radiosensitization by oxygen is much greater than 3 mmHg and is further increased by elevated levels of cysteine. Radiat. Res. 156, 388-398 (2001).
32. C. J. Koch, Oxygen sensor design: analysis and correction of problems associated with zero current, stability and structure. Adv. Exp. Med. Biol. 510, 151-156 (2003).
33. A. D. Horan, A. R. Giandomenico and C. J. Koch, Effect of oxygen on radiation-induced DNA damage in isolated nuclei. Radiat. Res. 152, 144-153 (1999).
34. W. Schaffner and C. Weissmann, A rapid, sensitive, and specific method for the determination of protein in dilute solution. Anal. Biochem. 56, 502-514 (1973).
35. H. Kajino, Y-Q. Chen, S. Chemtob, N. Waleh, C. J. Koch and R. I. Clyman, Tissue hypoxia inhibits prostaglandin and nitric oxide production and prevents ductus arteriosus reopening. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, 278-286 (2000).
36. E. Harlow and D. Lane, Using Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1998.
37. P. L. Olive, J. P. Banath and R. E. Durand, The range of oxygenation in SiHa tumor xenografts. Cancer Res. 158, 159-166 (2002).
38. T. M. Busch, S. M. Hahn, S. M. Evans and C. J. Koch, Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3, [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl) acetamide]. Cancer Res. 60, 2636-2642 (2000).
39. J. A. Raleigh, E. M. Zeman, M. Rathman, J. K. LaDine, J. M. Cline and D. E. Thrall, Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue. Int. J. Radiat. Oncol. Biol. Phys. 22, 403-405 (1992).
40. R. Tibes, Y. H. Qiu, Y. Lu, B. Hennessy, M. Andreeff, G. B. Mills and S. M. Kornblau, Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512-2521 (2006).
41. B. Jankovic, C. Aquino-Parsons, J. A. Raleigh, E. J. Stanbridge, R. E. Durand, J. P. Banath, S. H. MacPhail and P. L. Olive, Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin. Cytom. 70, 45-55 (2006).
42. P. L. Olive, R. E. Durand, J. A. Raleigh, C. Luo and C. Aquino-Parsons, Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br. J. Cancer 83, 1525-1531 (2000).
43. D. Vordermark and J. M. Brown, Evaluation of hypoxia-inducible factor-1a (HIF-1a) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. Int. J. Radiat. Oncol. Biol. Phys. 56, 1184-1193 (2003).
44. P. Wardman, Molecular structure and biological activity of hypoxic cell radiosensitizers and hypoxic specific cytotoxins. In Advanced Topics on Radiosensitizers of Hypoxic Cells (A. Breccia, C. Rimondi and G. E. Adams, Eds.), pp. 49-75. Plenum Press, New York, 1982.
45. M. F. Dennis, M. R. Stratford, P. Wardman and M. E. Watts, Cellular uptake of misonidazole and analogues with basic or acidic functions. Int. J. Radiat. Oncol. Biol. Phys. 47, 629-643 (1985).
46. M. I. Walton, N. M. Bleehen and P. Workman, The reversible Noxidation of the nitroimidazole radiosensitizer Ro 03-8799. Biochem. Pharmacol. 34, 3939-3940 (1985).
47. M. M. Kleiter, D. E. Thrall, D. E. Malarkey, X. Ji, D. Y. W. Lee, S-C. Chou and J. A. Raleigh, A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int. J. Radiat. Oncol. Biol. Phys. 64, 592-602 (2006).